Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$50.20
+1.3%		$48.49
$25.17
▼
$55.67
$8.39B0.342.24 million shs30,298 shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$38.00
+0.8%		$34.44
$19.72
▼
$40.30
$2.96B0.87964,322 shs19,455 shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$82.63
+0.4%		$74.80
$59.38
▼
$84.44
$9.81B0.851.78 million shs45,510 shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$54.40
-0.2%		$69.13
$40.03
▼
$86.74
$8.99B0.362.43 million shs97,884 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+1.10%-6.07%-9.25%+36.63%+86.55%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-0.97%+5.72%-1.77%+11.31%+69.85%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-0.33%+0.97%+3.55%+24.90%+39.39%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
+5.25%-2.63%-33.39%-27.59%+26.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$50.20
+1.3%		$48.49
$25.17
▼
$55.67
$8.39B0.342.24 million shs30,298 shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$38.00
+0.8%		$34.44
$19.72
▼
$40.30
$2.96B0.87964,322 shs19,455 shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$82.63
+0.4%		$74.80
$59.38
▼
$84.44
$9.81B0.851.78 million shs45,510 shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$54.40
-0.2%		$69.13
$40.03
▼
$86.74
$8.99B0.362.43 million shs97,884 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+1.10%-6.07%-9.25%+36.63%+86.55%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-0.97%+5.72%-1.77%+11.31%+69.85%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-0.33%+0.97%+3.55%+24.90%+39.39%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
+5.25%-2.63%-33.39%-27.59%+26.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.72
Moderate Buy$54.568.70% Upside
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.86
Moderate Buy$54.6243.73% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.54
Moderate Buy$81.60-1.25% Downside
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.77
Moderate Buy$94.6574.00% Upside

Current Analyst Ratings Breakdown

Latest CLDX, HALO, IONS, and ALKS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/3/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$72.00 ➝ $76.00
7/31/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
7/30/2026
Alkermes plc stock logo
ALKS
Alkermes
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
7/30/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$100.00 ➝ $95.00
7/30/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$125.00 ➝ $115.00
7/29/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$69.00
7/29/2026
Alkermes plc stock logo
ALKS
Alkermes
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$60.00 ➝ $61.00
7/29/2026
Alkermes plc stock logo
ALKS
Alkermes
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$48.00 ➝ $58.00
7/29/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$48.00 ➝ $72.00
7/28/2026
Alkermes plc stock logo
ALKS
Alkermes
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$43.00 ➝ $65.00
7/23/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.67B5.05$1.72 per share29.26$11.02 per share4.55
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$1.54M1,936.72N/AN/A$7.93 per share4.79
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.40B7.02$4.78 per share17.30$0.42 per share196.74
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$874.09M10.34N/AN/A$3.02 per share18.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$241.66M$0.38131.67209.15N/A3.96%4.15%2.19%N/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$2.7829.759.000.3423.13%187.91%21.92%8/6/2026 (Estimated)
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$381.39M-$3.46N/AN/AN/A-64.76%-111.08%-17.41%N/A

Latest CLDX, HALO, IONS, and ALKS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.06N/AN/AN/A$0.74 millionN/A
8/6/2026Q2 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.79N/AN/AN/A$402.28 millionN/A
5/11/2026Q1 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.54$1.60+$0.06$1.22$358.60 million$376.71 million
5/7/2026Q1 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.82
2.30
1.85
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
8.92
8.92
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
8.81
2.76
2.33
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
3.07
7.89
7.73

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
93.86%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.59%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5.20%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1.81%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050167.76 million160.06 millionOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15078.49 million74.41 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
390118.61 million115.65 millionOptionable
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1,402166.18 million163.18 millionOptionable

Recent News About These Companies

HC Wainwright Issues Negative Forecast for IONS Earnings
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-negative-forecast-for-ions-earnings-2026-08-04/
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
August 3 at 4:00 PM  |  fool.comhttps://www.fool.com/coverage/filings/2026/08/03/ionis-pharmaceuticals-director-hayden-buys-usd1-1-million-shares-what-does-this-mean-for-investors/
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock
August 3 at 11:53 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jpmorgan-chase-co-forecasts-strong-price-appreciation-for-ionis-pharmaceuticals-nasdaqions-stock-2026-08-03/
Carmignac Gestion Invests $3.98 Million in Ionis Pharmaceuticals, Inc. $IONS
August 3 at 4:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-carmignac-gestion-invests-398-million-in-ionis-pharmaceuticals-inc-ions-2026-08-03/
Ionis Pharmaceuticals, Inc. $IONS Stock Position Boosted by California State Teachers Retirement System
August 3 at 3:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ionis-pharmaceuticals-inc-ions-stock-position-boosted-by-california-state-teachers-retirement-system-2026-08-03/
Perceptive Advisors LLC Makes New $37.84 Million Investment in Ionis Pharmaceuticals, Inc. $IONS
August 2 at 6:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-perceptive-advisors-llc-makes-new-3784-million-investment-in-ionis-pharmaceuticals-inc-ions-2026-08-02/
HC Wainwright Cuts Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $115.00
August 2 at 2:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30935660
Ionis Pharmaceuticals (NASDAQ:IONS) Director Purchases $258,000.00 in Stock
August 1 at 5:51 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ions-insider-buying-and-selling-2026-08-01/
Groupama Asset Managment Purchases 57,651 Shares of Ionis Pharmaceuticals, Inc. $IONS
August 1 at 4:55 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-groupama-asset-managment-purchases-57651-shares-of-ionis-pharmaceuticals-inc-ions-2026-08-01/
Edgestream Partners L.P. Takes $5.13 Million Position in Ionis Pharmaceuticals, Inc. $IONS
August 1 at 4:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-edgestream-partners-lp-takes-513-million-position-in-ionis-pharmaceuticals-inc-ions-2026-08-01/
Empowered Funds LLC Has $7.75 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS
August 1 at 4:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-has-775-million-stock-holdings-in-ionis-pharmaceuticals-inc-ions-2026-08-01/
Ionis Pharmaceuticals (NASDAQ:IONS) Cut to "Sell" at Wall Street Zen
August 1 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30933463
Ionis Pharmaceuticals (NASDAQ:IONS) Lowered to "Sell" Rating by Wall Street Zen
August 1 at 1:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ionis-pharmaceuticals-nasdaqions-lowered-to-sell-rating-by-wall-street-zen-2026-08-01/
Ionis Pharmaceuticals (NASDAQ:IONS) Director Michael Hayden Buys 5,000 Shares
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ionis-pharmaceuticals-nasdaqions-director-michael-hayden-buys-5000-shares-2026-07-31/
Insider Buying: Ionis Pharmaceuticals (NASDAQ:IONS) Director Acquires $800,700.00 in Stock
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-buying-ionis-pharmaceuticals-nasdaqions-director-acquires-80070000-in-stock-2026-07-31/
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
July 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2965029/ions-beats-q2-earnings-sales-estimates-reiterates-26-outlook?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2965029
Ionis Pharmaceuticals (IONS) Q2 2026
July 30, 2026  |  247wallst.comhttps://247wallst.com/companies/ions/earnings/
Ionis Pharmaceuticals Inc (IONS) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and ...
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ionis-pharmaceuticals-inc-ions-q2-210251784.html
Ionis Pharmaceuticals (NASDAQ:IONS) Given New $95.00 Price Target at Wells Fargo & Company
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ionis-pharmaceuticals-nasdaqions-given-new-9500-price-target-at-wells-fargo-company-2026-07-30/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
July 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ionis-pharmaceuticals-inc---ions-302838827.html
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $115.00 by Analysts at HC Wainwright
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ionis-pharmaceuticals-nasdaqions-price-target-cut-to-11500-by-analysts-at-hc-wainwright-2026-07-30/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Rocket Lab Electron rocket on coastal launch pad with company logo overlay, symbolizing space tech integration strategy.
Rocket Lab’s Stock Drop Comes With a Bullish Twist
By Ryan Hasson | July 10, 2026
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
Illustration of a quantum computing chandelier with the IQM logo, surrounded by cryogenic quantum computer units in a lab.
IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave
By Nathan Reiff | July 10, 2026
Illuminated AV logo displayed on a riveted metal panel surrounded by cables and machinery components.
AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
By Jeffrey Neal Johnson | July 10, 2026
Alkermes stock logo

Alkermes NASDAQ:ALKS

$50.20 +0.67 (+1.34%)
As of 10:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$38.00 +0.31 (+0.82%)
As of 10:03 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$82.63 +0.36 (+0.44%)
As of 10:03 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Ionis Pharmaceuticals stock logo

Ionis Pharmaceuticals NASDAQ:IONS

$54.40 -0.09 (-0.17%)
As of 10:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas